US-based TerraPower announced that the TerraPower Isotopes team has distributed the first samples of Actinium-225 to two pharmaceutical companies. The Actinium-225 will be used as a starting material by these companies for research and development of advanced, targeted cancer treatments and in drug trials involving targeted alpha therapy in multiple disease areas.
“With this first round of samples, we are expanding the availability of this rare isotope, bringing the medical community closer to commercial sales of Actinium-225 and increasing widespread access for patients,” said TerraPower Isotopes President Scott Claunch. “Interest in Actinium-225 is high, and current capacity is short of drug development or commercialization requirements, which limits drug trials. Today marks the next step toward meeting global demand.”
Image courtesy of TerraPower
